

CORRECTION

Open Access




Correction: Combination of ferroptosis and pyroptosis dual induction by triptolide nano-MOFs for immunotherapy of Melanoma

Shengmei Wang¹, Qiuyan Guo¹, Rubing Xu¹, Peng Lin¹, Guoyan Deng² and Xinhua Xia^{1*}

Correction: Journal of Nanobiotechnology (2023) 21:383
<https://doi.org/10.1186/s12951-023-02146-0>

Following publication of the original article, the authors found errors in the quantification in Fig. 7B. “The results showed that compared with PBS or TFBE, the proportion of activated DCs (CD86⁺CD11c⁺) in TPL@TFBF tumor tissues increased from ~26.8 to ~57.3%, indicating an increased level of DCs maturation after TPL@TFBF treatment (Fig. 7A, B and Additional file 1: Fig. S13).”

Incorrect Fig. 7B



Corrected Fig. 7B




Fig. 7B Quantification of the results from (A)

The complete corrected Fig. 7 is given below.
The original article has been corrected.

The original article can be found online at <https://doi.org/10.1186/s12951-023-02146-0>.

*Correspondence:

Xinhua Xia
xiaxinhua001@hnuoc.edu.cn

¹ School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, Hunan, China

² The First Hospital of Hunan University of Chinese Medicine, Changsha 410007, Hunan, China



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.




Fig. 7 **A** Flow cytometry analysis of CD11c⁺CD86⁺ cells, CD3⁺CD4⁺ cells and CD3⁺CD8⁺ cells in tumor tissues from mice in each group after treatment with different formulations. **B–D** Quantification of the results from **A**. **E–G** Expression levels of CD86, CD8 and CD4 in tumor tissues from different groups. **H–J** Quantification of the results from **E–G**. The levels of **(K)** IL-6, **(L)** TNF-α and **(M)** IL-1β in tumor tissues from mice in different groups after different treatments. Data are expressed as the mean ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001

Published online: 15 July 2024

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.